Friday, June 8, 2012

Natl Lemonade Days Weekend Jun 8-10 to support pediatric cancer


Get your lemonade stand on this weekend, June 8-June 10, to support Pediatric Cancer. June 8-10 is the official National Lemonade Days weekend - a three day effort to raise $1 million in the battle against childhood cancer. Parents can learn more about participating in 2012 National Lemonade Days and find tips for running a lemonade stand for charity at http://www.AlexsLemonade.org.

Check out this press release below; how LEGO supported this cause.

Full press release follows.

LEGO® Friends and Alex's Lemonade Stand Foundation Build World's Largest LEGO Lemonade Stand

-Company encourages children nationwide to make 2012 the biggest and most successful National Lemonade Days weekend ever to fight childhood cancer-

PHILADELPHIA, June 8, 2012 /PRNewswire/ -- LEGO® Friends, a new construction toy theme designed to engage more children in LEGO play, announced today that it will build the world's largest LEGO lemonade stand June 7-8. The build will take place in front of Philadelphia's National Constitution Center (NCC) in an effort to inspire children nationwide to create their own lemonade stand to benefit Alex's Lemonade Stand Foundation (ALSF), a non-profit organization dedicated to finding better treatments and - ultimately - a cure for childhood cancer. 
On Thursday, June 7 and Friday, June 8, LEGO Friends invites residents of and visitors to Philadelphia, hometown of ALSF namesake, Alex Scott, to help build a lemonade stand out of LEGO bricks. Once completed, the stand will serve Swiss Premium™ Lemonade by Lehigh Valley Dairy Farms and become a backdrop to other LEGO building activities on Saturday, June 9 to benefit ALSF. In addition to hosting interactive programs to honor Alex Scott and her legacy, the NCC is offering free admission to children 8 years old and under who donate to ALSF at the NCC June 7 - 9.
"Earlier this year we set out to invite more children to the LEGO construction experience with the new LEGO Friends play theme and in only four months we've inspired creativity among a new and growing audience of children," said Michael McNally, brand relations director for LEGO Systems. "It moved us to celebrate others who have inspired creativity and we were instantly blown away by the story of Alex's ingenuity to redesign the traditional lemonade stand into a powerful fundraising vehicle. It is our goal to encourage that same creativity in children everywhere by helping to build the biggest National Lemonade Days weekend ever." 
While June 8-10 is the official National Lemonade Days weekend - a three day effort to raise $1 million in the battle against childhood cancer - children and families who are not able to participate in thePhiladelphia event are encouraged to consider running their own lemonade stands any time during the year. Participants choose a day to host their stand and register with ALSF at which point they get a dedicated fundraising page and a pack of materials to help with the stand. Parents can learn more about participating in 2012 National Lemonade Days and find tips for running a lemonade stand for charity at http://www.AlexsLemonade.org.
"We're excited to partner with LEGO Friends to help drive awareness for National Lemonade Days and the fight against childhood cancer," said Liz Scott, Alex's mom and Co-Executive Director of ALSF. "Each year we hear from parents that participation in National Lemonade Days helped show their children that a small act can make a big difference in the community, even when it comes to a challenge as serious as childhood cancer."
LEGO Friends is a new construction play theme designed to engage more girls in the positive benefits of LEGO play. The collection is based on insights from girls worldwide on what they would like to see in a LEGO building experience: realistic building and role-play, plenty of details, and a chance to remodel, redecorate, and redesign in a character-based world. To find building instructions for creating a LEGO lemonade stand to add to any LEGO town collection, visit http://www.buildtogether.com. 
To check out a time lapse video of the world's largest LEGO Lemonade Stand as it is constructed visit Comcast Xfinity TV's LEGO On Demand channel.
Newsrooms can access b-roll of the build at www.TheNewsmarket.com.
About LEGO Systems, Inc.LEGO Systems Inc. is the Americas division of the LEGO Group, a privately-held, family-owned firm based in Billund, Denmark. The company is committed to the development of children's creative and imaginative abilities through high-quality, creatively educational play materials. For more information, visitwww.LEGO.com
LEGO and the LEGO logo are trademarks of The LEGO Group. © 2012 The LEGO Group.
About Alex's Lemonade Stand Foundation Alex's Lemonade Stand Foundation (ALSF) emerged from the front yard lemonade stand of cancer patient Alexandra "Alex" Scott (1996-2004). In 2000, 4-year-old Alex announced that she wanted to hold a lemonade stand to raise money to help find a cure for all children with cancer. Since Alex held that first stand, the Foundation bearing her name has evolved into a national fundraising movement, complete with thousands of supporters across the country carrying on her legacy of hope. To date, Alex's Lemonade Stand Foundation, a registered 501(c)3 charity, has raised more than $50million toward fulfilling Alex's dream of finding a cure, funding over 200 research projects nationally.
SOURCE LEGO Systems, Inc.
CONTACT: Amanda Santoro, LEGO Systems, Inc., +1-860-763-7834, amanda.santoro@lego.com
Web Site: http://www.lego.com 

CSL Behring Receives FDA Orphan Drug Designation for rIX-FP


CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B). Full press release follows.

SOURCE CSL Behring

KING OF PRUSSIA, Pa., June 8, 2012 /PRNewswire/ -- CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The Orphan Drug Designation is granted for the treatment and prophylaxis of bleeding episodes in patients with congenital factor IX deficiency (hemophilia B). The designation includes routine prophylaxis treatment, control and prevention of bleeding episodes, and prevention and control of bleeding in perioperative settings.
CSL Behring is developing this therapy in collaboration with its parent company CSL Limited (ASX: CSL).
"CSL Behring is pleased to have achieved this important regulatory milestone for our recombinant factor IX," said Val Romberg, Senior Vice President, Research and Development at CSL Behring. "It represents yet another advance that our company is making in the area of recombinant factor development and is extremely encouraging."
CSL Behring has engineered rIX-FP to extend the half-life of Factor IX through genetic fusion with recombinant albumin. Albumin has been chosen as the ideal recombinant genetic fusion partner for coagulation factor proteins due to its long physiological half-life. In addition, albumin has been shown to have a good tolerability profile, low potential for immunogenic reactions and a well-known mechanism of clearance compared to some other technologies. The cleavable linker connecting recombinant factor IX and recombinant albumin has been specifically designed to preserve the native function of the coagulation factor in the fusion protein, while benefiting from recombinant albumin's long physiological half-life.
The FDA's Orphan Drug Designation program provides orphan status to unique drugs and biologics, defined as those intended for the safe and effective treatment or prevention of rare diseases that affect fewer than 200,000 people in the U.S.
About Hemophilia
Hemophilia is a congenital bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints or internal organs. In nearly all cases, it affects only males. The disease is caused by deficient or defective blood coagulation proteins known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX. Hemophilia A affects approximately 1 in 5,000 to 10,000 people. Hemophilia B affects approximately 1 in 25,000 to 50,000 people. The recommended treatment for patients who are factor deficient is to treat by replacement factor therapy. A complication in some patients is the development of inhibitory antibodies (inhibitors) to FVIII or FIX which renders replacement therapy ineffective. This can occur in up to 25 percent of hemophilia A patients and around 5 percent of hemophilia B patients. One treatment option for these patients is recombinant activated factor VII (called a bypassing agent) which can be used to achieve hemostasis without the need for factor VIII or IX.
About CSL BehringCSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For information: www.cslbehring.com.

Media contact: Sheila A. Burke, CSL Behring, 610-878-4209 (US)
SOURCE CSL Behring

Thursday, June 7, 2012

Seeking Communications Mgr for Healthcare Corporation, Nashville


Seeking Communications Manager, for a healthcare corporation located in Nashville, TN. See complete job profile, below.

TITLE: Communications Manager
LOCATION: Nashville TN
TYPE: Corporation, HCIT (health care IT) and health services sector
YEARS EXPERIENCE: 3-7+ years
TO APPLY: email resume to Deborah Kaufman Healthcare Recruiter, at deborah@healthcare-recruiting.com. Please put in subject line: Communications Manager-Nashville

 DESCRIPTION: The Communications Manager will serve as the day-to-day lead on communications and media relations activities for the interactive youth health company. The position will have a unique opportunity to work with progressive public relations and social media firms, along with company leadership, to create a buzz around the Corporation’s growing portfolio of interactive products focused on improving youth health.
Key Responsibilities:
●            Participate in the development of the company's communication strategy
●            Serve as the project lead working with the company's public relations and social media firms from concept development through execution
●            Draft, edit media relations materials (press releases, op-eds, etc.)
●            Work closely with company's product and marketing teams to distill key product value propositions for targeted audiences
●            Develop and foster relationships with journalists, bloggers and key opinion leaders
focused on youth health and wellness
●            Closely coordinate with customer base to develop partner press opportunities
●            Coordinate various communication touch points, including social media and company blog communication
●            Work with senior team members to identify, secure, and prepare for relevant press
opportunities and speaking engagements
●            Ability to review and analyze data to identify and exploit pearls of information which can be used as proof points for broader PR initiatives.
●            Generate new ideas and media opportunities to ensure brands’ success
●            Analyze the quantitative and qualitative outputs of PR programs and placements to
maximize effectiveness and ROI.
Required Skills:
●            3-7 years of public relations, corporate communications experience
●            Establish relationships with industry relevant PR contacts
●            Strong written and verbal communication skills
●            Preferential consideration given to candidates who worked within digital media
companies
●            Proven experience with Facebook, Twitter, LinkedIn, Pinterest
●            Strong drive and ownership mindset; ability to own issues and see them through
resolution
●            Strong leadership presence; effective cross-functional driver
●            Proven ability to support multiple business units and engage with senior leadership ●            Must thrive in a fast-paced, fluid environment and be able to prioritize multiple
responsibilities, projects
The position is based in Nashville, TN and occasional travel is required for relevant industry events, press opportunities and media tours.

Mobile Health Adoption News, PwC Study


Consumers Are Ready to Adopt Mobile Health Faster than the Health Industry is Prepared to Adapt, Finds PwC Study on Global mHealth Adoption.

Full press release follows.
SOURCE: PwC

NEW YORK, June 7, 2012 /PRNewswire/ -- Widespread adoption of mobile technology in healthcare, ormHealth, is now viewed as inevitable in both developed and emerging markets around the world, but the pace of adoption will likely be led by emerging markets and lag consumer demand, according to a new global study conducted for PwC Global Healthcare by the Economist Intelligence Unit (EIU).  
The ground breaking study, Emerging mHealth: paths for growth , found that consumers have high expectations for mHealth, particularly in developing economies as mobile cellular subscriptions there become ubiquitous. In emerging markets, consumers perceive mHealth as a way to increase access to healthcare while patients in developed markets see it as a way to improve the convenience, cost and quality of healthcare.
According to the report, if the promise of mHealth is realized by consumers, the impact on healthcare delivery could be significant and fundamentally alter traditional relationships within the healthcare industry.  The use of mHealth and speed of adoption will be determined in each country by stakeholders' response to mHealth as a disruptive innovation to overcome structural impediments and align interests around patients' needs and expectations.
"Despite demand and the obvious potential benefits of mHealth, rapid adoption is not yet occurring. The main barriers are not the technology but rather systemic to healthcare and inherent resistance to change," said David Levy, MD, global healthcare leader, PwC.  "Though many people think mobile health will be ancillary or bolted on to the healthcare industry, we look at it differently:  mHealth is the future of healthcare, deeply integrated into delivery that will be better, faster, less expensive and far more customer-focused."
In the report, the EIU examines the current state and potential of mHealth (defined as the provision of healthcare or health-related information through the use of mobile devices) and the barriers to adoption and opportunities for companies seeking growth in the mHealth market.  The report includes findings of two surveys conducted by the EIU:  one of consumers and one of physicians and government and private payers in 10 markets, including Brazil, China, Denmark, Germany, India, South Africa, Spain, Turkey, the UK and the US.  
The consumer survey found:
  • Roughly one-half of consumers predict that within the next three years, mHealth will improve the convenience (46 percent), cost (52 percent) and quality (48 percent) of their healthcare.
  • Fifty-nine percent of emerging market patients use at least one mHealth application or service, compared with 35 percent in the developed world. Nearly half of consumers said they expect mHealth will change the way they manage chronic conditions (48 percent), their medication (48 percent) and their overall health (49 percent).  Six in ten consumers (59 percent) expect mHealth to change the way they seek information on health issues and 48 percent expect it to change the way they communicate with physicians.  
  • Among consumers who already are using mHealth services, 59 percent said they have replaced some visits to doctors or nurses. 
  • The top three reasons consumers want to use mHealth is to have more convenient access to their doctor or healthcare provider (46 percent), to reduce out-of-pocket healthcare costs (43 percent) and to take greater control over their health (32 percent).
  • Sixty percent of consumers said they believe doctors are not as interested in mHealth as patients and technology companies are.
The study found that physicians and payers are more cautious than consumers in their outlook for mHealth. Specifically:
  • Nearly two-thirds (64 percent) of doctors and payers said that mHealth offers exciting possibilities but there are too few proven business models.  In addition, the effectiveness of mHealth changing patient behaviour is evolving.  For example, more than two-thirds of consumer respondents who have used mHealth wellness or fitness applications with manual data entry discontinued it after the first six months.
  • Only 27 percent of physicians encourage patients to use mHealth applications to become more active in managing their health, and 13 percent of physicians actually discourage it.
  • Forty-two percent of doctors surveyed worry that mHealth will make patients too independent. 
  • Payers appear to be far more supportive of mHealth than physicians. Forty percent of payers compared to 25 percent of physicians encourage patients to let doctors monitor their health and activities using mHealth services and devices. 
  • Payers and providers both cited multiple barriers to the adoption of mHealth, notably the complexity and scope of change associated with mHealth. Public sector doctors and payers cited lack of existing technology as the biggest barrier to greater use of mHealth adoption.  Sixty-three percent of physicians in the private sector versus only 40 percent in the public sector have access to wireless connectivity at work.
  • Forty-five percent of doctors and payers said that the application of inappropriate regulations originally developed for earlier technologies is slowing the adoption of mHealth.
  • More than one quarter – 27 percent of doctors and 26 percent of payers – cite an inherently conservative culture as a leading barrier to the adoption of mHealth.  
"The adoption of mobile health in emerging markets versus developed markets is a paradox," saidChristopher Wasden, EdD, global healthcare innovation Leader, PwC. "In developed markets, mHealth is perceived as disrupting the status quo, whereas in emerging countries it is seen as creating a new market, full of opportunity and growth potential.  In younger, developing economies, healthcare is less constrained by healthcare infrastructure and entrenched interests. Consumers are more likely to usemobile devices and mHealth applications, and more payers are willing to cover the cost of mHealth services."
According to PwC, innovators seeking opportunities in mHealth, including telecommunications and technology companies, must work to overcome the barriers slowing widespread adoption of mHealth.   They can help to alleviate healthcare's resistance to change by focusing less on the technology and more on effective, customer-focused solutions that add value for health organizations and patient quality of life.
In its analysis, PwC identifies strategic considerations for companies active in the mHealth arena. In addition, PwC will publish a series of insights over the next several months on the evolving mHealth landscape with perspective on what it means for stakeholders, including government and regulators, pharmaceutical and life science companies, payers and providers.
A full copy of the EIU report is available for download at www.pwc.com/mhealth.  
About PwC's Health Industries Group
PwC's Health Industries Group (www.pwc.com/us/healthindustries) is a leading advisor to public and private organizations across the health industries, including healthcare providers, pharmaceuticals, health and life sciences, payers, employers, academic institutions and non-health organizations with significant presence in the health market. Follow PwC Health Industries at http://twitter.com/PwCHealth.
About the PwC network 
PwC US helps organizations and individuals create the value they're looking for. We're a member of the PwC network of firms with 169,000 people in more than 158 countries. We're committed to delivering quality in assurance, tax and advisory services. Tell us what matters to you and find out more by visiting us at www.pwc.com/us.
© 2012 PricewaterhouseCoopers LLP, a Delaware limited liability partnership. All rights reserved.
PwC refers to the US member firm, and may sometimes refer to the PwC network. Each member firm is a separate legal entity. Please see www.pwc.com/structure for further details.
This content is for general information purposes only, and should not be used as a substitute for consultation with professional advisors.
SOURCE PwC
CONTACT: Lisa An, PwC Global Healthcare, lisa.an@us.pwc.com, +1-646-471-1376; or Lisa Stearns, The Hubbell Group, Inc., lstearns@hubbellgroup.com, +1-781-878-8882
Web Site: http://www.pwc.com/us 

Wednesday, June 6, 2012

Eye Health News: Bausch + Lomb Completes ISTA Pharma Acquisition


Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals

Transaction Broadens Bausch + Lomb's Pharmaceutical Portfolio and Enhances its Pipeline of Late-Stage Products.

Full press release follows.
SOURCE Bausch + Lomb

MADISON, N.J., June 6, 2012 /PRNewswire/ -- Bausch + Lomb, the global eye health company, announced today that it has completed its acquisition of ISTA Pharmaceuticals, Inc., a leading pharmaceutical company.  The addition of ISTA bolsters Bausch + Lomb's product portfolio and pipeline, increasing the company's therapeutic offerings for physicians and their patients and creating opportunity for future growth. 
"This combination is a big step for Bausch + Lomb and an exciting development for eye health.  Together, we are building a high-performance company that can deliver even more benefits for the patients and customers we serve," said Brent Saunders, president and chief executive officer, Bausch + Lomb. "ISTA's business complements our own very well, and we are excited about the opportunities this transaction creates." 
ISTA's four prescription products, BROMDAY™, BEPREVE®, ISTALOL®, and VITRASE®, will complement Bausch + Lomb's existing prescription ophthalmology products, including Lotemax® andBesivance®, and branded OTC eye vitamins PreserVision® and Ocuvite®. Bausch + Lomb's pharmaceutical pipeline now has nearly double the number of mid-to late-stage innovations. The newly combined pipeline includes PROLENSA™, T-PRED™, BEPOMAX™ and BEPOSONE™, ISTA's candidates to treat ocular inflammation and pain and allergy-related nasal conditions, and Bausch + Lomb's pharmaceutical innovations, including the first of a new class of ocular anti-inflammatory agents as well as a promising approach to reducing intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension.
"The addition of ISTA creates exciting new opportunities for Bausch + Lomb's rapidly growing pharmaceutical business," said Daniel M. Wechsler, executive vice president and president, Bausch + Lomb Global Pharmaceuticals. "ISTA is an exceptional company with strong formulation expertise, a robust portfolio of therapeutic offerings and a promising pipeline.  And, importantly, our new colleagues from ISTA share our passion for innovation and delivering products that will help patients see better and improve the quality of their lives."  
The all-cash transaction with ISTA, valued at approximately $500 million, is expected to add more than$150 million to Bausch + Lomb's annualized sales and be accretive to Bausch + Lomb's EBITDA this year.
Bausch + Lomb is committed to ensuring its combination with ISTA is as seamless as possible for its customers, suppliers and other partners, and will be providing updates throughout the integration process. A list of frequently asked questions regarding today's news can be found at www.bausch.com.          
About Bausch + Lomb 
Bausch + Lomb is one of the best-known and most respected healthcare companies in the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 11,000 people worldwide. Its products are available in more than 100 countries. More information is available at www.bausch.com.
News Media Contacts :
Teresa Panas
Director, Global Pharmaceutical Communications
+1 973-360-6382 or teresa.panas@bausch.com 
Adam Grossberg
Vice President, Global Communications and Investor Relations 
+1 973-360-6439 or adam.grossberg@bausch.com 
SOURCE Bausch + Lomb
Web Site: http://www.bausch.com 

Tuesday, June 5, 2012

Boston Children's Hospital Ranked #1, US News & World Rpt


Boston Children's Hospital Ranks #1 on U.S. News & World Report Best Children's Hospitals Honor Roll. Ranked in the Top 4 in all 10 Specialty Areas.

Full press release is below.
SOURCE: Boston Children's Hospital

BOSTON, June 5, 2012 /PRNewswire-USNewswire/ -- Boston Children's Hospital ranks first in the U.S. News & World Report's 2012-13 Best Children's Hospitals Rankings Honor Roll. With evaluation results released today, Boston Children's is first in Cardiology & Heart Surgery, Nephrology, Neurology & Neurosurgery; second in Cancer, Diabetes & Endocrinology, Gastroenterology and Urology; third in Neonatology and Orthopedics; and fourth in Pulmonology. Boston Children's partners with Dana-Farber Cancer Institute to operate the Dana-Farber/Children's Hospital Cancer Center – an integrated pediatric oncology program.
"We're honored by this recognition and view it as a challenge to continue to work tirelessly to improve the quality of care given to each and every family that comes through our doors," says James Mandell, MD, CEO of Boston Children's.
The rankings feature 50 hospitals in each of 10 pediatric specialties: cancer, cardiology and heart surgery, diabetes and endocrinology, gastroenterology, neonatology, nephrology, neurology and neurosurgery, orthopedics, pulmonology, and urology. Eighty hospitals across the country ranked in one or more specialties. Among hospitals in Massachusetts, Boston Children's was the only hospital ranked in the top 30 in any of the specialty areas.  
"The rankings reflect the dedication of our caregivers, researchers, staff, volunteers and referring doctors across Boston Children's community of care," adds Sandra Fenwick, President and COO of Boston Children's. "Our staff represents the finest in their fields, and it's only through working together that we can provide such exceptional care."
This year, U.S. News surveyed 178 pediatric centers to obtain hard data such as availability of key resources and ability to prevent complications and infections. The hospital survey made up 75 percent of the evaluation to determine rankings. A separate reputational survey in which 1,500 pediatric specialists—150 in each specialty—were asked where they would send the sickest children in their specialty made up the remaining 25 percent of data used for evaluation.
Founded in 1869 as a 20-bed hospital for children, Boston Children's Hospital has been ranked as one of the nation's best pediatric hospitals by U.S.News & World Report for the past 21 years. Boston Children's is the primary pediatric teaching hospital of Harvard Medical School and the largest provider of health care to Massachusetts children. In addition to 395 pediatric and adolescent inpatient beds and 228 outpatient programs, Boston Children's houses the world's largest research enterprise based at a pediatric medical center , where its discoveries benefit both children and adults. More than 1,100 scientists, including nine members of the National Academy of Sciences, 11 members of the Institute of Medicine and nine members of the Howard Hughes Medical Institute comprise Boston Children's research community. For more information about the hospital visit: www.childrenshospital.org/newsroom.
CONTACT:
Rob Graham
Boston Children's Hospital
617-919-3110
rob.graham@childrens.harvard.edu
SOURCE Boston Children's Hospital

Friday, June 1, 2012

Oncology News: ColoPrint for Colon Cancer Prognosis and Prediction


Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction

Agendia's Microarray-based Gene Expression Profile Provides Critical Additional Information for Treatment Decisions for Stage II Colon Cancer Patients

Full press release is below.
SOURCE: Agendia
IRVINE, Calif. and AMSTERDAM, June 1, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the launch of its ColoPrint microarray-based 18-gene expression signature for predicting the risk of distant recurrence for stage II colon cancer patients who have undergone surgery.
ColoPrint provides a definitive relapse risk assessment for 100 percent of all stage II patients and eliminates the gray area of indeterminate results found in 70 percent of patients using clinical and pathologic factors such as T4-stage and Microsatellite Instability (MSI) status. In combination with clinical factors, ColoPrint further individualizes the relapse risk assessment for colon cancer patients. This definitive risk stratification tool improves the identification of patients most likely to benefit from adjuvant therapy.
"ColoPrint's definitive results (either high or low risk with no in between) will enable doctors to choose treatment plans for colon cancer patients that are customized for each patient's individual needs," saidDavid Macdonald, Agendia CEO. "We expect ColoPrint to be well received amongst physicians and patients for a more personalized management of this disease."
Colon cancer is the third most common cancer in men and women worldwide. As with most cancers, the stage at which colon cancer is diagnosed is a key factor in determining long-term survival outcomes. A key challenge in colon cancer management is determining the risk of relapse for patients with stage II colon cancer and deciding if these patients should receive adjuvant treatment, such as radiotherapy or chemotherapy.
Surgery alone typically cures 80 percent of stage II colon cancer patients, and identifying which patients will benefit from chemotherapy remains a challenge. Today, approximately 30-50 percent of stage II colon cancer patients receive adjuvant chemotherapy in the U.S. However, due to the fact that the benefit of chemotherapy is small and its use is controversial, the number of patients receiving adjuvant chemotherapy varies significantly from physician to physician and hospital to hospital. There are few reliable clinical factors to identify patients who are more likely to benefit from adjuvant treatment, and now ColoPrint provides a definitive risk stratification for every stage II colon cancer patient.
About Agendia
Agendia is a leading molecular diagnostic company that develops and markets genomic-based diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer Symphony™ suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients.  Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, an alternative therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.
In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.
For more information, please visit www.agendia.com.
SOURCE Agendia
CONTACT: Peri Brauth, Post+Beam, +1-646-442-2769, brauth@postandbeam.is